Complete remission in a colon cancer patient with a large, irresectable liver metastasis after XELOX/cetuximab/bevacizumab treatment

Onkologie

Volumn 31, Issue 8-9, 2008, Pages 464-467

  Weihrauch, Martin R ^a,c   Stippel, Dirk ^a   Fries, Jochen W U ^a   Arnold, Dirk ^b   Bovenschulte, Henning ^a   Coutelle, Oliver ^a   Hacker, Ulrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Stage IV

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; OXALIPLATIN; VASCULOTROPIN ANTIBODY;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; COLORECTAL CANCER; HISTOLOGY; HUMAN; LIVER METASTASIS; LOADING DRUG DOSE; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 52249094900     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142388     Document Type: Article

References (16)

1. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318.
2. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254-1262.
3. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
4. Van Cutsem E, Nowacki I, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Koehne C: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc Am Soc Clin Oncol 2007;25:Ab4000.
5. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-1319.
6. Jaeck D, Nakano H, Bachellier P, Inoue K, Weber JC, Oussoultzoglou E, Wolf P, Chenard-Neu MP: Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002;9:430-438.
7. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D: Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13:1271-1280.
8. Wicherts DA, Haas RJ, Levi F, Aloia T, Paule B, Bralet M, Kunstlinger F, Azoulay D, Castaing D, Adam R: Complete pathological response of colorectal liver metastases after neoadjuvant chemotherapy: myth or reality? J Clin Oncol 2007;25:Ab4063.
9. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-3945.
10. Aloia T, Levi F, Wicherts DA, Haas RJ, Paule M, Bralet M, Bouchahda D, Azoulay D, Castaing D, Adam R: Hepatic resection following rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2008;25:4061.
11. Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H: Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 2007;30:637-643.
12. Ramos FJ, Tabernero J: Cetuximab and chemotherapy for patients with unresectable CRC liver metastasis: are we changing the natural course of the disease? Onkologie 2007;30:602-604.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
14. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
15. Hecht JR, Chidiac T, Mitchell E: An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Proceedings of the 9th World Congress on Gastrointestinal Cancer. Ann Oncol 2007 2008;18:Ab0-0033.
16. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ: A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-738.